Nasdaq
$4.41▲ 0.08%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $251.1MShares out 57.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
15- 1d agoRegular26.10.24 03:38SCHEDULE 13DOwnership#●●●#●●●
ABEONA THERAPEUTICS INC.Bullish
James Russell Revocable Trust acquired a total of 56,755 shares of Abeona Therapeutics Inc. through open-market purchases between August 17, 2026, and October 15, 2026. The shares were purchased at prices ranging from approximately $4 to $6 per share, indicating an increase in insider holdings.…more
$4.41+0.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.30Overnight26.09.30 10:484Ownership
ABEONA THERAPEUTICS INC.
Insider Seshadri Vishwas of Abeona Therapeutics Inc. filed a Form 4 on September 29, 2026, reporting changes in beneficial ownership of securities. This filing serves as an official record of the insider's equity position adjustment.…more
$4.41+0.08%vs prev closeView filingShare - 9.30Overnight26.09.30 10:484Ownership
ABEONA THERAPEUTICS INC.
Joseph Walter Vazzano, an insider at Abeona Therapeutics Inc., filed a Form 4 statement of changes in beneficial ownership on September 29, 2026. This filing officially reports the changes in the insider's stock holdings to the SEC.…more
$4.41+0.08%vs prev closeView filingShare
14 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 1d agoRegular26.10.24 03:43#●●●
Abeona Therapeutics: James Russell Trust Increases Stake to 6.1%
A 13D filing reveals that the James Russell Revocable Trust has increased its stake in Abeona Therapeutics to 6.1% as of October 15, 2026. This disclosure reflects a change in major shareholding status.…more
$4.41+0.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 10.2Pre-market26.10.02 20:30
●●●●●●●● ●●●●● ●●●●●●
Abeona Therapeutics has granted restricted stock awards to two new employees as a material inducement for their hiring under Nasdaq rules. This move represents a standard practice for talent acquisition and has a neutral impact on the company's operations.…more
$4.41+0.08%vs prev close - 9.18Pre-market26.09.18 20:30
●●●●●●●● ●●●●● ●●●●●●
Abeona Therapeutics' former gene therapy candidate FAYUVI has received FDA approval under its partner Ultragenyx. This milestone entitles Abeona to receive future commercial milestone payments and royalties from product sales.…more
$4.41+0.08%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report